, Tracking Stock Market Picks
Enter Symbol:
Genomic Health, Inc. (GHDX) [hlAlert]

up 11.29 %

Genomic Health, Inc. (GHDX) downgraded to Underperform by BofA/Merrill

Posted on: Tuesday,  Oct 1, 2013  8:25 AM ET by BofA/Merrill

BofA/Merrill rated Underperform Genomic Health, Inc. (NASDAQ: GHDX) on 10/01/2013, when the stock price was $29.75. Since
then, Genomic Health, Inc. has lost 10.15% as of 01/06/2016's recent price of $26.73.
If you would have followed this BofA/Merrill's recommendation on GHDX, you would have gained 11.29% of your investment in 827 days.

Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. It launched its first test, Oncotype DX, which has been shown to predict the likelihood of breast cancer recurrence and chemotherapy benefit in early stage breast cancer patients. The Oncotype DX assay represents the first diagnostic gene expression test on the market that provides consistent results across multiple independent trials having breast cancer patients, including a large validation study of The New England Journal of Medicine.

Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/1/2013 8:25 AM Sell
as of 12/13/2013
1 Week up  9.94 %
1 Month up  12.53 %
3 Months down  -1.98 %
1 YTD up  15.49 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/18/2013 8:25 AM Hold
8/16/2012 8:25 AM Buy

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy